Belgium
I work at the intersection of clinical practice, EU institutional affairs, and market access strategy. What I deliver: → EU regulatory intelligence translated into market access strategy (HTA Regulation, Pharma Package, ATMPs) → Stakeholder engagement across institutions, patient organisations and payers → Policy advisory for pharma companies, health NGOs and patient associations Institutional track record: → Expert member, CEESP / Haute Autorité de Santé — HTA & health economics evaluations (2022–present) → EHC Representative, EU HTA Stakeholder Network — implementation of EU Regulation 2021/2282 → Trainee, European Commission — DG SANTE, Unit D2 (Health Products) → CAST Laureate, Political Affairs My edge: 8 years as a physiotherapist before European affairs. I understand clinical endpoints, patient realities, and how EU institutions work from the inside. That combination is rare. Co-author of 8 peer-reviewed publications https://orcid.org/0000-0001-9632-8331
Evidence-Based Policy Making -Utilize data-driven insights and rigorous analysis to inform policy recommendations and decisions. -Translate complex research findings into actionable strategies for improving healthcare outcomes. -Advocate for policies grounded in scientific evidence to address pressing healthcare challenges effectively. Patient-Partnership Approach -Champion patient perspectives and preferences in policy development and implementation. -Collaborate with stakeholders to ensure policies prioritize patient needs and experiences. -Promote initiatives that empower patients to actively participate in their care decisions and healthcare system improvements. Sustainability and Ecology -Integrate principles of sustainability into healthcare policies and practices to minimize environmental impact. -Advocate for ecologically conscious healthcare solutions that reduce carbon footprint and promote resource efficiency. -Support initiatives that align healthcare delivery with sustainable development goals for a healthier planet and population.
Representing the EHC at the EU HTA Stakeholder Network, established by the European Commission to coordinate implementation of EU Regulation 2021/2282 on Health Technology Assessment. Capacity building across 40+ national member organisations from Ireland to Kyrgyzstan.
-Reviewing clinical, economic, and ethical evidence for public health recommendations and technology appraisals -Patient focus approaches in decision-making processes -Providing opinions on the efficiency and budgetary impact of technologies
DG SANTE Unit D2 Policy Analysis and Development -Drafting pharmaceutical legislation package -Participating in the coordination of the NCAPR (National Competent Authorities and Pricing and Reimbursement) group, -Collaborating with various stakeholders to address affordability challenges and enhance access to medicines (WHO-Europe, OECD, French representation) Stakeholder Engagement and Collaboration -Engaging with diverse stakeholders, including national competent authorities, industry representatives, patient advocacy groups, and healthcare professionals, to gather insights and feedback on pharmaceutical legislation revision -Facilitating discussions and consultations within the NCAPR group to exchange best practices, identify barriers, and explore solutions to improve access to affordable medicines, including biosimilars -Collaborating with internal and external partners to ensure alignment of policies with EU health objectives and regulatory frameworks Research and Analysis -Conducting research and analysis on market dynamics, pricing mechanisms, and regulatory frameworks impacting the affordability and accessibility of medicines in the EU -Assessing the potential impact of proposed regulatory changes on healthcare systems, patients, and industry stakeholders -Providing evidence-based recommendations to support decision-making processes and policy development initiatives aimed at enhancing affordability and accessibility of pharmaceuticals
The Association Francaise des Hemophiles is a non-profit organisation that represents 15.000 people living with a rare bleeding disorder. AFH works in France and worldwide in partnership with the European Hemophilia Consortium and the World Federation of Hemophilia The AFH advocacy team aims to enhance drug safety, healthcare access and improve the quality of life in France. As drug chairman, my focus is medicines access, medicines safety, and community preparedness for new pharmaceuticals considered as game changers.